Pharming Group NV (PHAR) News
Filter PHAR News Items
PHAR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PHAR News Highlights
- For PHAR, its 30 day story count is now at 2.
- Over the past 22 days, the trend for PHAR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- III, RARE and DRUG are the most mentioned tickers in articles about PHAR.
Latest PHAR News From Around the Web
Below are the latest news stories about PHARMING GROUP NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming has engaged wit |
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibThe multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective p |
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalLeiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetab |
Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific MeetingLeiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster presentations by the Company or its collaborators regarding leniolisib and RUCONEST® at the International Primary Immunodeficiencies Congress (IPIC) and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in November. IPIC, Rotterdam, The Netherlands, November 8 - 10, 2023 Approaches to family testing for auto |
Pharming Group to participate in November investor conferencesLeiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of November: Stifel 2023 Healthcare Conference, New York, November 14-15Anurag Relan, Chief Medical Officer will participate in a fireside chat, question and answer session on Tuesday, November 14 at 08:35 am ET/14:35 CET.Jefferies London Healthcare Conference 2023, London, U.K |
Pharming Group reports third quarter 2023 financial resultsPharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®Nine month year to date 2023 revenues increased 9% to US$164.1 million, compared to nine month year to date 2022RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to the second quart |
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
Pharming Group to report third quarter 2023 financial results on October 26Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 EDT on October 26, 2023. To participate in the conference call, please register in advance using the link below. Once registered, dial-in informat |
Pharming Group reports on results of the 2023 Extraordinary General Meeting of ShareholdersLeiden, The Netherlands, September 25, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Dr. Richard Peters as Non-Executive director for a period of four years. As a result, Dr. Peters succeeds Mr. Paul Sekhri as Chair of the Board of Directors with immediate effect. Deborah Jorn, Vice-Chair of the |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayPre-market stock movers are a hot topic this morning and we're checking on the biggest ones investors will want to watch on Friday! |